Fund: ISHNUSBI
iShares Nasdaq US Biotechnology UCITS ETF USD | |
IE00BYXG2H39 | |
19-10-2017 | |
Equity | |
Equity Sectors - Health Care | |
BlackRock iShares | |
BlackRock Advisors (UK) Limited | |
USD | |
1,000 | |
5% |
1M | 3M | 6M | 9M | 1R | 3R p.a. | 5R p.a. | 7R p.a. | 10R p.a. | od vnizku p.a. | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Výkonnosť fondu | -2.28% | 0.59% | 12.49% | 10.15% | 10.06% | -1.31% | 5.58% | - | - | N/A | |
Priemerná výkonnosť (36 meraní) | -0.09% | 0.43% | 5.79% | - | - | ||||||
Volatilita od priemernej výkonnosti | 8.94% | 28.40% | 10.01% | - | - |
Long | Short | Net | |
---|---|---|---|
Stock | 99.78% | 99.78% | |
Bond | |||
Other | 0.00% | 0.00% | |
Cash | 0.22% | 0.22% |
Aktíva | 4,451 mil. |
Počet akcíí | 221 |
Počet dlhopisov | 0 |
Priebež. popl. | 0.35 |
z toho Mng. popl. | 0.35 |
Výk. prémia | |
Trans. popl. |
Dividenda | |
Dividendový výnos | |
Rozhodný dátum | |
Frekvencia výplaty |
Giant | 5.14% |
Large | 32.46% |
Medium | 28.59% |
Small | 18.25% |
Micro | 14.23% |
P/E | 15.45% |
P/BV | 3.21% |
Healthcare | 99.78% |
Derivatives | 0.22 |
Výnos do splatnosti p.a. | |
Modifikovaná durácia |
United States | 88.36% |
Canada | 0.57% |
Latin America | |
United Kingdom | 5.28% |
Eurozone | 2.99% |
Europe - ex Euro | 1.66% |
Europe - Emerging | |
Africa | |
Middle East | |
Japan | |
Australasia | |
Asia - Developed | 0.13% |
Asia - Emerging | 0.79% |
Emerging Market | 0.79% |
Developed Country | 98.98% |
Not Classified |
Spoločnosť | Subsektor | Váha | Spoločnosť | Subsektor | Váha |
---|---|---|---|---|---|
Regeneron Pharmaceuticals Inc | Healthcare | 8.67% | Vertex Pharmaceuticals Inc | Healthcare | 8.49% |
Amgen Inc | Healthcare | 7.42% | Gilead Sciences Inc | Healthcare | 7.05% |
Moderna Inc | Healthcare | 3.87% | AstraZeneca PLC ADR | Healthcare | 3.76% |
Biogen Inc | Healthcare | 3.25% | Illumina Inc | Healthcare | 2.21% |
Alnylam Pharmaceuticals Inc | Healthcare | 1.92% | Biomarin Pharmaceutical Inc | Healthcare | 1.65% |